JP2003526362A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526362A5
JP2003526362A5 JP2001567304A JP2001567304A JP2003526362A5 JP 2003526362 A5 JP2003526362 A5 JP 2003526362A5 JP 2001567304 A JP2001567304 A JP 2001567304A JP 2001567304 A JP2001567304 A JP 2001567304A JP 2003526362 A5 JP2003526362 A5 JP 2003526362A5
Authority
JP
Japan
Prior art keywords
mva
cell line
cells
grow
vaccinia virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001567304A
Other languages
English (en)
Japanese (ja)
Other versions
JP4759201B2 (ja
JP2003526362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/002703 external-priority patent/WO2001068820A1/en
Publication of JP2003526362A publication Critical patent/JP2003526362A/ja
Publication of JP2003526362A5 publication Critical patent/JP2003526362A5/ja
Application granted granted Critical
Publication of JP4759201B2 publication Critical patent/JP4759201B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001567304A 2000-03-14 2001-03-10 変異ワクシニアウイルスアンカラ(mva)の改変株 Expired - Fee Related JP4759201B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000410 2000-03-14
DKPA200000410 2000-03-14
DK200000410 2000-03-14
PCT/EP2001/002703 WO2001068820A1 (en) 2000-03-14 2001-03-10 Altered strain of the modified vaccinia virus ankara (mva)

Publications (3)

Publication Number Publication Date
JP2003526362A JP2003526362A (ja) 2003-09-09
JP2003526362A5 true JP2003526362A5 (cg-RX-API-DMAC7.html) 2011-01-27
JP4759201B2 JP4759201B2 (ja) 2011-08-31

Family

ID=8159327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001567304A Expired - Fee Related JP4759201B2 (ja) 2000-03-14 2001-03-10 変異ワクシニアウイルスアンカラ(mva)の改変株

Country Status (25)

Country Link
US (1) US6682743B2 (cg-RX-API-DMAC7.html)
EP (1) EP1263936B1 (cg-RX-API-DMAC7.html)
JP (1) JP4759201B2 (cg-RX-API-DMAC7.html)
KR (1) KR100880765B1 (cg-RX-API-DMAC7.html)
CN (1) CN1291012C (cg-RX-API-DMAC7.html)
AT (1) ATE305030T1 (cg-RX-API-DMAC7.html)
AU (1) AU780696B2 (cg-RX-API-DMAC7.html)
BR (1) BR0109158A (cg-RX-API-DMAC7.html)
CA (1) CA2397675C (cg-RX-API-DMAC7.html)
CZ (1) CZ293690B6 (cg-RX-API-DMAC7.html)
DE (1) DE60113512T2 (cg-RX-API-DMAC7.html)
DK (1) DK1263936T3 (cg-RX-API-DMAC7.html)
EE (1) EE05633B1 (cg-RX-API-DMAC7.html)
ES (1) ES2249430T3 (cg-RX-API-DMAC7.html)
HK (1) HK1052725B (cg-RX-API-DMAC7.html)
HU (1) HU228691B1 (cg-RX-API-DMAC7.html)
IL (3) IL150736A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02008873A (cg-RX-API-DMAC7.html)
NO (1) NO20024246L (cg-RX-API-DMAC7.html)
NZ (1) NZ521270A (cg-RX-API-DMAC7.html)
PL (1) PL205922B1 (cg-RX-API-DMAC7.html)
RU (1) RU2280075C2 (cg-RX-API-DMAC7.html)
SI (1) SI1263936T1 (cg-RX-API-DMAC7.html)
UA (1) UA84388C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001068820A1 (cg-RX-API-DMAC7.html)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7097842B2 (en) 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
EP1357127A1 (de) * 2002-04-10 2003-10-29 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
EP1420822B2 (en) * 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
UA82479C2 (uk) * 2002-05-16 2008-04-25 Бавариан Нордика А/С Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
AU2003264144C1 (en) * 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
JP5052893B2 (ja) 2003-02-20 2012-10-17 アメリカ合衆国 ポックスベクターにおける新規の挿入部位
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
US7423155B2 (en) 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
DE602004009743T2 (de) 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
EP1835031A1 (en) 2006-03-14 2007-09-19 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans
US7607323B1 (en) 2007-10-16 2009-10-27 Hall Charles F Curl resistant shirt collar and method of fabricating same
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
US9005632B2 (en) 2009-11-20 2015-04-14 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
US9011874B2 (en) 2009-11-20 2015-04-21 Takeda Vaccines, Inc. Compositions, methods and uses for poxvirus elements in vaccine constructs
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
WO2012151272A2 (en) 2011-05-02 2012-11-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
US20170021009A1 (en) * 2014-03-10 2017-01-26 Arizona Board Of Regents On Behalf Of Arizona State Heat Inactivated Poxvirus Improves Vaccination Results
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
NL2014148B1 (en) 2015-01-16 2017-01-05 Univ Erasmus Med Ct Rotterdam Combination vaccine for camelids.
EP4122492A1 (en) * 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
US12239699B2 (en) 2018-09-11 2025-03-04 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2023077147A2 (en) 2021-11-01 2023-05-04 Pellis Therapeutics, Inc. T-cell vaccines for patients with reduced humoral immunity
EP4519445A4 (en) * 2022-05-04 2026-06-24 Univ Maryland RNA VECTORS WITH HAIRPIN INSERTS
US20230364227A1 (en) 2022-05-12 2023-11-16 Pellis Therapeutics, Inc. Poxvirus adjuvant for t-cell vaccination
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
FR3171450A1 (fr) 2025-01-17 2026-07-24 Odimma Therapeutics Virus enveloppé pour la transfection d’acides nucléiques exogènes.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341245C (en) * 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
RU2076735C1 (ru) * 1994-03-23 1997-04-10 ГНЦВБ "Вектор" Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
WO1999018994A1 (en) * 1997-10-15 1999-04-22 Asahi Kasei Kogyo Kabushiki Kaisha Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution
JP3736622B2 (ja) * 2001-06-15 2006-01-18 セイコーエプソン株式会社 ライン駆動回路、電気光学装置及び表示装置

Similar Documents

Publication Publication Date Title
CN100335619C (zh) 大规模生产病毒抗原的方法
JP5154632B2 (ja) ウイルス増殖法
SI1434858T1 (sl) Postopek za pomnoĹľevanje poksvirusa v razmerah brez seruma
WO2003088994A3 (en) Modified vaccinia virus ankara for the vaccination of neonates
CN1418248A (zh) 修饰的安卡拉牛痘病毒(mva)的变株
CN107190022A (zh) 一种快速构建禽传染性支气管炎病毒反向遗传株的方法
Shi et al. Medium pH between 5.5 and 7.5 has minimal effects on tissue culture of apple
CN107299078A (zh) 一株适应全悬浮培养的猫肾细胞系f‑81 s及其应用
Goussard et al. The elimination of fanleaf virus from grapevines using in vitro somatic embryogenesis combined with heat therapy
CN107523555A (zh) 获得病毒的方法
WO2024012483A1 (zh) 一种基因缺失的减毒非洲猪瘟病毒毒株及其构建方法和应用
CN116286685A (zh) 一种基于CRISPR-Cas9技术的表达H9N2禽流感病毒XZ491毒株HA蛋白的重组血清4型禽腺病毒及其制备方法
CN1723285A (zh) 重组的mva及其产生方法
CN104087549B (zh) 高产杆状病毒的昆虫细胞系及其应用
CN116676274B (zh) 可自失活噬菌体及其制备方法和应用
CN111676198A (zh) 快速构建鸭坦布苏病毒反向遗传株的方法
JP2019511208A5 (cg-RX-API-DMAC7.html)
JP2005521423A5 (cg-RX-API-DMAC7.html)
RU2009137571A (ru) Способ наращивания рекомбинантного аденовируса человека
JP2003500059A5 (cg-RX-API-DMAC7.html)
Křižan et al. The effect of media composition on multiplication of grape rootstocks in vitro
CN111642395A (zh) 一种番茄抗病毒突变体的筛选方法
CN114410678B (zh) 一种建立农杆菌介导中国水仙高效遗传转化体系的方法
CN117925543A (zh) 复制缺陷型痘苗病毒天坛株及其应用
Fabry et al. High density microcarrier cell culture for viral vaccine production.